These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1659 related articles for article (PubMed ID: 27455225)

  • 41. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review).
    Huang J; Li H; Ren G
    Int J Oncol; 2015 Sep; 47(3):840-8. PubMed ID: 26202679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT).
    Cho ES; Kang HE; Kim NH; Yook JI
    Arch Pharm Res; 2019 Jan; 42(1):14-24. PubMed ID: 30649699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance.
    Luo M; Brooks M; Wicha MS
    Curr Pharm Des; 2015; 21(10):1301-10. PubMed ID: 25506895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The roles of the COX2/PGE2/EP axis in therapeutic resistance.
    Tong D; Liu Q; Wang LA; Xie Q; Pang J; Huang Y; Wang L; Liu G; Zhang D; Lan W; Jiang J
    Cancer Metastasis Rev; 2018 Sep; 37(2-3):355-368. PubMed ID: 30094570
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Epithelial-Mesenchymal Transition at the Crossroads between Metabolism and Tumor Progression.
    Fedele M; Sgarra R; Battista S; Cerchia L; Manfioletti G
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.
    Shibue T; Weinberg RA
    Nat Rev Clin Oncol; 2017 Oct; 14(10):611-629. PubMed ID: 28397828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The correlation between cancer stem cells and epithelial-mesenchymal transition: molecular mechanisms and significance in cancer theragnosis.
    Lei ZN; Teng QX; Koya J; Liu Y; Chen Z; Zeng L; Chen ZS; Fang S; Wang J; Liu Y; Pan Y
    Front Immunol; 2024; 15():1417201. PubMed ID: 39403386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Microenvironment of Lung Cancer and Therapeutic Implications.
    Mittal V; El Rayes T; Narula N; McGraw TE; Altorki NK; Barcellos-Hoff MH
    Adv Exp Med Biol; 2016; 890():75-110. PubMed ID: 26703800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Knockdown of E-cadherin induces cancer stem-cell-like phenotype and drug resistance in cervical cancer cells.
    Sharma A; Kaur H; De R; Srinivasan R; Pal A; Bhattacharyya S
    Biochem Cell Biol; 2021 Oct; 99(5):587-595. PubMed ID: 33677985
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement.
    Bharti R; Dey G; Mandal M
    Cancer Lett; 2016 May; 375(1):51-61. PubMed ID: 26945971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIF-1α induces the epithelial-mesenchymal transition in gastric cancer stem cells through the Snail pathway.
    Yang SW; Zhang ZG; Hao YX; Zhao YL; Qian F; Shi Y; Li PA; Liu CY; Yu PW
    Oncotarget; 2017 Feb; 8(6):9535-9545. PubMed ID: 28076840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Bibenzyl from Dendrobium ellipsophyllum inhibits epithelial-to-mesenchymal transition and sensitizes lung cancer cells to anoikis.
    Chaotham C; Pongrakhananon V; Sritularak B; Chanvorachote P
    Anticancer Res; 2014 Apr; 34(4):1931-8. PubMed ID: 24692728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact.
    Foroni C; Broggini M; Generali D; Damia G
    Cancer Treat Rev; 2012 Oct; 38(6):689-97. PubMed ID: 22118888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.
    Choupani J; Mansoori Derakhshan S; Bayat S; Alivand MR; Shekari Khaniani M
    J Cell Physiol; 2018 Jun; 233(6):4443-4457. PubMed ID: 29194618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.
    Wang Z; Li Y; Ahmad A; Azmi AS; Kong D; Banerjee S; Sarkar FH
    Drug Resist Updat; 2010; 13(4-5):109-18. PubMed ID: 20692200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.
    Liu Z; Li Q; Li K; Chen L; Li W; Hou M; Liu T; Yang J; Lindvall C; Björkholm M; Jia J; Xu D
    Oncogene; 2013 Sep; 32(36):4203-13. PubMed ID: 23045275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging role of F-box proteins in the regulation of epithelial-mesenchymal transition and stem cells in human cancers.
    Song Y; Lin M; Liu Y; Wang ZW; Zhu X
    Stem Cell Res Ther; 2019 Apr; 10(1):124. PubMed ID: 30999935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.
    Ranji P; Salmani Kesejini T; Saeedikhoo S; Alizadeh AM
    Tumour Biol; 2016 Oct; 37(10):13059-13075. PubMed ID: 27561758
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
    Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
    Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.